Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07282717

Fibroblast Line Evaluation for COL5A eXpression and Thoracic Aortic Aneurysms: in Vitro Characterization of Cutaneous Fibroblasts in Adult Patients

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
IRCCS Policlinico S. Donato · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study examines adults with COL5A gene mutations to understand why some develop aortic aneurysms while others do not. Participants provide a small skin biopsy, and researchers analyze fibroblasts to evaluate collagen production, extracellular matrix organization, and connective-tissue signaling pathways. The goal is to identify biological differences that may explain variable vascular risk and support future personalized monitoring and treatment strategies.

Detailed description

Individuals with mutations in the collagent type V, alpha (COL5A) gene show variable clinical outcomes. While some develop aortic aneurysms, others with the same mutation remain free of cardiovascular complications. The mechanisms driving this variability are not fully understood. This study aims to investigate biological differences at the cellular level by analyzing fibroblasts derived from a small skin biopsy. Fibroblasts play a key role in the production and organization of type V collagen and the extracellular matrix. Researchers will: Grow fibroblasts from participants' skin samples. Assess cell growth, migration, and extracellular matrix formation. Measure the quantity and type of collagen produced. Evaluate molecules involved in collagen breakdown and repair. The study compares individuals with COL5A mutations who have documented aortic aneurysms to those with the same mutation but no vascular involvement. Analyses will also consider differences among family members who share the same genetic variant. By characterizing fibroblast behavior, the study seeks to clarify why some individuals develop aortic disease while others remain unaffected. Findings may help identify cellular features associated with increased or reduced vascular risk and guide future strategies for monitoring, prevention, and personalized care in patients with COL5A mutations.

Conditions

Timeline

Start date
2026-01-13
Primary completion
2028-01-01
Completion
2028-12-01
First posted
2025-12-15
Last updated
2026-02-02

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT07282717. Inclusion in this directory is not an endorsement.